Unity Biotechnology Public Company

Primary contact

Unity Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. The company's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.
Primary contact

Funding 💰

Total $208.8M
Select investors ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, Venrock, Bezos Expeditions, Mayo Clinic Ventures, Altitude Life Science Ventures, EcoR1 Capital
Last update: May 15, 2018